.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's wrong w/ R&R?
AEZS news:
Æterna Zentaris to Raise US$15 Million in Registered Direct Offering
QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$15 million of securities in a registered direct offering. Under the terms of a Securities Purchase Agreement, the Company will sell to such institutional investors an aggregate of approximately 11.1 million common shares of its capital at a price of US$1.35 per share and issue warrants to acquire an aggregate of approximately 4.4 million common shares at an exercise price of US$1.50 per share.
The warrants to purchase additional common shares of Æterna Zentaris will be exercisable six months following their date of issuance and will expire on the fifth-year anniversary of the date on which they become exercisable. All of the securities were offered pursuant to an effective shelf registration statement filed in the United States. Proceeds from the transaction will be used for general corporate purposes, including clinical development, capital expenditures and for working capital. The offering is expected to be consummated no later than April 20, 2010, subject to customary closing conditions.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ:RODM - News), acted as the exclusive placement agent for the transaction.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. A shelf registration statement relating to the common shares and warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed by the Company with the SEC and the Canadian securities regulatory authorities. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company or by contacting Æterna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5.
About Æterna Zentaris Inc.
Æterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy News releases and additional information are available at http://www.aezsinc.com/.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.
BioShockers 2Q 2010 Watch List
RNN – release of Serdaxin and Zoraxel P2a results
GNVC – momentum play, possible bounce coming
QCOR – advisory committee meeting for Acthar on May 6
AVNR – release of full P3 results
ACUR – advisory committee meeting for Acurox on 4/23
POZN – PDUFA date on 4/30
CYTX – APOLLO trial results to be presented at meeting on May 7
BTIM – stem cell momentum play
INHX – release of interim FV100 data
HRBR – release of Triolex P2 results in obese type 2 diabetes patients
HLCS – bounce play
BNVI – possible partner for Menerba
IVD – possible FDA decision on MAGO4S 510K submission
ISCO.OB – stem cell momentum play
THTCF.PK (also on Toronto exchange: TH.TO) – advisory committee meeting on May 27
If any of these need corrections or if you have a stock you think should be added, let me know.
RNN doesn't look so great anymore... IMO, unless a miracle happens, Serdaxin is finished.
GNVC is a great bounce play, IMO. If their atonal therapy (TherATOH) works (and preclinical results look really promising), GNVC will fly...
GLTA.
UPDATE 2-Rexahn antidepressant fails in early mid-stage trial
Tue Apr 13, 2010 3:38pm EDT
Rexahn Pharmaceuticals, Inc.
* Overall study fails to achieve statistical significance
* Says patients on 5 mg Serdaxin improved in MADRS scores * Shares down 50 pct (Recasts; adds company comments, updates stock movement)
By Krishnakali Sengupta
BANGALORE, April 13 (Reuters) - Rexahn Pharmaceuticals Inc (RNN.A) said its experimental antidepressant drug Serdaxin did not achieve statistical significance in a mid-stage study, sending its shares down 50 percent in afternoon trade.
The study, however, showed the drug to be safe and well tolerated without the appearance of serious side effects that are commonly linked to certain currently marketed drugs for the treatment of major depressive disorder, Rexahn said in a statement.
"This study was a proof-of-concept study from our perspective. We were looking for a strong signal, which we did get in the severe patient population", President Rakesh Soni told Reuters.
Although the overall study -- on 77 patients -- did not achieve statistical significance, results from the subgroup analysis showed the drug to significantly improve Montgomery-Asberg Depression Rating (MADRS) scores in patients treated with 5 mg of Serdaxin for 8 weeks, compared to a dummy drug.
The MADRS rating is used to measure the severity of depressive episodes in patients with mood disorders.
The company said it plans to start a second mid-stage clinical trial in the second half this year and is currently in talks with several major pharmaceutical companies to co-develop the drug.
Soni said the second mid-stage study will enroll about 400 patients and will evaluate the drug's efficacy against similar drugs.
"We are in talks with several companies, evaluating partnerships, and we expect much higher milestone payments for the drug than what we had with Teva," Soni added.
In 2009, Rexahn entered into an agreement with Teva Pharmaceutical Industries (TEVA.TA) (TEVA.O) for the development of one its preclinical novel anti-cancer compounds, for which it is expected to receive a couple of hundred million dollars in a milestone payments.
Shares of the company fell to $1.82, but recovered some of the losses and were trading down 48 percent at $1.89 in afternoon trade Tuesday on the American Stock Exchange. (Reporting by Krishnakali Sengupta; Editing by Unnikrishnan Nair)
Great news... 0.99 pre-market, w/ a high of $1.21.
GLTA.
$9.85 PM...
GLTA.
IVAX Diagnostics Increases Product Line Through Distribution Agreement with
Biomerica
Adds Unique Rapid Point-of-Care Tests and 33 New ELISA Test Kits to be Sold by
Diamedix in the U.S. and Delta Biologicals in Global Markets
MIAMI & IRVINE, Calif., Apr 13, 2010 (BUSINESS WIRE) -- IVAX Diagnostics, Inc.
(IVD), a fully integrated in vitro diagnostics company, and Biomerica, Inc.
(BMRA), a global biomedical company, have signed a two-year agreement for the
distribution of Biomerica's products in the U.S. and globally, with certain
country and product exclusions.
The agreement provides IVAX Diagnostics the rights for its Diamedix Corporation
and Delta Biologicals S.r.l. subsidiaries to distribute Biomerica's suite of
products which includes 33 ELISA (Enzyme-Linked Immunosorbent Assay) test kits in
the areas of diabetes, gastrointestinal disease and bone/mineral disorders, and
more than 26 Rapid Point-of-Care tests. The products will be marketed under the
Biomerica name, or, if certain initial sales levels are achieved, under the
Diamedix brand in the U.S. and Delta Biologicals brand internationally.
Dr. Charles Struby, CEO and President of IVAX Diagnostics, said, "This agreement
with Biomerica is expected to not only broaden and enhance our ELISA suite of
products by adding GI, diabetes and bone/mineral testing products to our line of
autoimmune test kits, but also expand our entry into the Rapid Point-of-Care
testing market, a global market that is estimated to be $10.3 billion. We expect
Biomerica's products to significantly enhance our ability to offer unique and
innovative tests to the approximately 600 installed Mago(R) instruments that are
being used by our customers. This agreement is another step toward our goal of
expanding our innovative diagnostics products, and increasing our presence in
both the U.S. and international markets. We are pleased to be working with
Biomerica and bringing their novel tests to the marketplace."
Zackary Irani, CEO of Biomerica, said, "IVAX Diagnostics' customer base of nearly
600 installed Mago(R) instruments offers both our companies a significant
opportunity to increase sales. As our tests complement those already sold by
Diamedix and Delta Biologicals, we believe their experienced sales forces and
ability to reach global markets, will produce positive results."
About Biomerica , Inc.
Biomerica, Inc. (http://www.biomerica.com) is a global biomedical company that
develops, manufactures and markets advanced diagnostic products used at the
point-of-care (in home and in physicians' offices ) and in hospital/clinical
laboratories for the early detection of medical conditions and diseases. The
Company's products are designed to enhance the health and well being of people,
while reducing total healthcare costs. Biomerica primarily focuses on products
for diabetes, gastrointestinal disease and esoteric testing.
About IVAX Diagnostics, Inc.
IVAX Diagnostics, Inc. (http://www.ivaxdiagnostics.com), headquartered in Miami,
Florida, is a fully integrated in vitro diagnostics company that develops,
manufactures and distributes in the United States and internationally,
proprietary diagnostic reagents, test kits and instrumentation, primarily for
autoimmune and infectious diseases, through its three subsidiaries: Diamedix
Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc.
Safe Harbor Statement
Except for the historical matters contained herein, statements in this press
release are forward-looking and are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect
the business and prospects of IVAX Diagnostics, Inc., including, without
limitation: the risks and uncertainties associated with IVAX Diagnostics'
agreement with Biomerica, including, without limitation, that anticipated levels
of sales may not be achieved under the agreement, that the agreement may not be
able to expand the product lines and product markets in which IVAX Diagnostics
currently operates and expects to operate in the future, that the agreement may
not assist IVAX Diagnostics in its goal of increasing its product lines and
expanding its reach in the U.S. and in international markets, and that the
agreement may not provide IVAX Diagnostics with, or otherwise allow IVAX
Diagnostics to achieve, its intended results, whether business, financial or
otherwise; and other risks and uncertainties that may cause results to differ
materially from those set forth in the forward-looking statements. In addition to
the risks and uncertainties set forth above, investors should consider the
economic, competitive, governmental, technological and other risks and
uncertainties discussed in IVAX Diagnostics' filings with the Securities and
Exchange Commission, including, without limitation, the risks and uncertainties
discussed under the heading "Risk Factors" in such filings.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for
forward-looking statements. Certain information included in this press release
(as well as information included in oral statements or other written statements
made or to be made by Biomerica contains statements that are forward-looking;
such as statements relating to intended launch dates, sales potential,
significant benefits, market size, growth of business, favorable positions,
expansion, expected orders, leading market positions, anticipated future revenues
or production volume of the Company, success of product and new product
offerings. Such forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results in the future,
and accordingly, such results may differ materially from those expressed in any
forward-looking statements made by or on behalf of Biomerica. The potential risks
and uncertainties include, among others, fluctuations in the Company's operating
results due to its business model and expansion plans, downturns in international
and or national economies, the Company's ability to raise additional capital, the
competitive environment in which the Company will be competing, and the Company's
dependence on strategic relationships. The Company is under no obligation to
update any forward-looking statements after the date of this release.
SOURCE: IVAX Diagnostics, Inc.
Company Contact:
IVAX Diagnostics
Dr. Charles R. Struby, CEO & President, 305-324-2300
or
Biomerica, Inc.
Zackary Irani, CEO, 949-645-2111
or
Investor Relations Contact:
Porter, LeVay & Rose, Inc.
Linda Decker, Vice President
212-564-4700
Copyright Business Wire 2010
Cytomedix Announces Going Concern Qualification
ROCKVILLE, Md., Apr 12, 2010 (GlobeNewswire via COMTEX) -- Cytomedix, Inc. (GTF)
announced today that its audited financial statements for the fiscal year ended
December 31, 2009, included in its Annual Report on Form 10-K filed on March 29,
2010, contained a going concern qualification from its independent registered
accounting firm.
This announcement is required by NYSE Amex Company Guide Section 610(b), which
requires separate disclosure of receipt of an audit opinion containing a going
concern qualification. This announcement does not represent any change or
amendment to the company's financial statements or to its Annual Report on Form
10-K for the fiscal year ended December 31, 2009.
About Cytomedix
Cytomedix is a biotechnology company that develops, sells, and licenses
regenerative biological therapies, to primarily address the areas of wound care,
inflammation, and angiogenesis. The Company currently markets the AutoloGelTM
System, a device for the production of platelet rich plasma ("PRP") gel derived
from the patient's own blood. The AutoloGelTM System is cleared by the Food and
Drug Administration ("FDA") for use on a variety of exuding wounds. The Company
is currently pursuing a multi-faceted strategy to penetrate the chronic wound
market with its AutoloGelTM System. We are also pursuing opportunities for the
application of AutoloGelTM and PRP technology into other markets such as hair
transplantation and orthopedics, as well as actively seeking complementary
products for the wound care market. The Company also seeks to monetize other
product candidates in its pipeline through strategic partnerships, out-licensing,
or sale. Most notably is its anti-inflammatory peptide (designated "CT-112") that
has shown promise in pre-clinical testing. Additional information regarding
Cytomedix is available at http://www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are
forward-looking statements that are intended to fall within the safe harbor rule
for such statements under the Private Securities Litigation Reform Act of 1995.
The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict or control,
including among others, viability and effectiveness of the Company's sales
approach and overall marketing strategies, the outcome of development or
regulatory review of CT-112, commercial success or acceptance by the medical
community, competitive responses, the Company's ability to raise additional
capital and to continue as a going concern, its ability to successfully
commercialize its product in Japan under the terms of the license agreement, and
Cytomedix's ability to execute on its strategy to market the AutoloGel(TM) System
as contemplated. These forward-looking statements are subject to known and
unknown risks and uncertainties that could cause actual events to differ from the
forward-looking statements. More information about some of these risks and
uncertainties may be found in the reports filed with the Securities and Exchange
Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and
rapidly changing business and regulatory environment, thus new or unforeseen
risks may arise. Accordingly, investors should not place any reliance on
forward-looking statements as a prediction of actual results. Except as is
expressly required by the federal securities laws, Cytomedix undertakes no
obligation to update or revise any forward-looking statements, whether as a
result of new information, changed circumstances or future events or for any
other reason.
This news release was distributed by GlobeNewswire, http://www.globenewswire.com
SOURCE: Cytomedix, Inc.
CONTACT:Cytomedix, Inc.
David Jorden, Executive Board Member
Andrew Maslan, CFO
(240) 499-2680
Lippert/Heilshorn & Associates
Anne Marie Fields
(212) 838-3777
afields@lhai.com
Bruce Voss
(310) 691-7100
bvoss@lhai.com
Cytomedix Acquires Angel Whole Blood Separation System and activAT Autologous
Thrombin Processing Kit From Sorin Group for $7 Million
Apr 12, 2010 (GlobeNewswire via COMTEX) --
Synergistic Products Expand Customer Base, Bring $5 Million in Annual
Sales
Conference Call Begins April 13th at 10:00 a.m. Eastern Time
ROCKVILLE, Md., April 12, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (GTF) (the
"Company"), a leading developer of biologically active regenerative therapies for
wound care, inflammation and angiogenesis, today announced the closing of an
agreement with Sorin Group (Milan: SORN) ("Sorin"), a global leader in the
treatment of cardiovascular diseases, to acquire the Angel(R) Whole Blood
Separation System ("Angel") and activAT(R) Autologous Thrombin Processing Kit
("activAT") for $7 million in cash, to be paid in installments over the next two
and one-half years. Together these products had sales of approximately $5 million
in 2009, of which over 90% were from high-margin, single-use disposable products.
The Company also announced that it has raised gross proceeds of $3.65 million in
a private placement of securities with both new and existing stockholders. Under
the terms of the private placement, Cytomedix issued 3,650 shares of a $1,000
stated value preferred stock that is convertible into the Company's common stock
at $0.44 per share and carries a 10% annual dividend to be paid quarterly in cash
or common stock at the Company's option. In addition, the Company issued
4,128,631 warrants to purchase its common stock, exercisable at $0.54 per share.
The warrants are exercisable immediately and expire on April 9, 2015. The
proceeds from this private placement are being used to fund the Sorin asset
purchase and for general corporate and working capital purposes.
"This highly accretive transaction with Sorin is transformational for Cytomedix,
and reflects our strategic commitment to build a growing franchise of
biologically active regenerative therapies," said Martin Rosendale, Chief
Executive Officer of Cytomedix. "Angel and activAT are excellent additions to our
PRP portfolio and have a business model that mirrors our own. We know this
technology well, and these products will provide us with immediate access to
surgical markets with proven products whose prospects, we believe, will be
significantly enhanced by Cytomedix's focused clinical and scientific marketing
approach."
"In addition to providing us with an established revenue stream, we believe these
products will be complementary to the AutoloGel(TM) System, our FDA-cleared
device for the production of PRP gel derived from the patient's own blood that is
used for the management of a variety of exuding wounds. This acquisition is also
synergistic with our planned efforts to expand our presence in the orthopedic
surgery market and has the potential to enhance our efforts to secure U.S.
reimbursement for the AutoloGel system," continued Mr. Rosendale. "We are
delighted now to have best-in-class products for the surgical suite, and a
best-in-class product for wound healing."
Used primarily in operating rooms, the Angel Whole Blood Separation System
consists of a blood processing device and disposable products used for separation
of whole blood into red cells, platelet poor plasma and platelet rich plasma
("PRP"). The Angel System processes a determined volume of anticoagulated whole
blood from a patient and separates it so that these autologous components are
then available for clinical use. The Angel System received market clearance from
the U.S. Food and Drug Administration ("FDA") in August 2005. Sales of the Angel
device and disposables for 2009 were approximately $4.8 million (over 90% in the
U.S.), representing an increase of approximately 7% over 2008 sales. The activAT
Autologous Thrombin Processing Kit is designed to produce autologous thrombin
serum from platelet poor plasma. The activAT kit is sold exclusively in Europe
and Canada, where it provides a completely autologous, safe alternative to
bovine-derived products. Sales of this product were approximately $0.2 million in
2009.
Michel Darnaud, President, Cardiopulmonary Business Unit and Intercontinental,
Sorin Group, stated, "We are pleased to enter into an agreement to sell these
non-core assets to Cytomedix, and we count on Cytomedix to maintain the same high
level of customer service, support and product excellence that our customers have
come to expect from Sorin."
Under the asset purchase agreement, Cytomedix will acquire, among other things,
all rights to the Angel and activAT products, including related trademarks,
patents, intellectual property, product inventory and other related assets. In
addition, Sorin will provide certain support and services to facilitate the
transition contemplated under the agreements with Cytomedix. Cytomedix expects to
add additional personnel to its sales infrastructure in the coming year.
Cytomedix's current eight-person sales team will provide sales and marketing
support for the Angel and activAT products, while maintaining focus on the
AutoloGel System.
Maxim Group LLC served as financial advisor to Cytomedix on this transaction.
All securities described in this news release were sold to "accredited investors"
as defined under federal securities laws in reliance upon an exemption from
registration. All conversions of the convertible preferred stock and exercises of
the warrants sold in this private placement in excess of 19.99% of the currently
outstanding number of common shares are subject to shareholder approval in
compliance with the NYSE Amex requirements. For a complete description of the
foregoing offering and terms of the underlying securities, please refer to the
Company's Current Report on Form 8-K filed with the Securities and Exchange
Commission on April 12, 2010.
Conference Call
Cytomedix will hold a conference call to discuss this announcement beginning at
10:00 a.m. Eastern time on April 13, 2010. Shareholders and other interested
parties may participate in the call by dialing 866-713-8564 (domestic) or
617-597-5312 (international) and entering passcode 49760117. The call will also
be broadcast live on the Internet at http://www.streetevents.com,
http://www.fulldisclosure.com and http://www.cytomedix.com.
A replay of the conference call will be accessible two hours after its completion
through 11:59 p.m. Eastern time on April 19, 2010 by dialing 888-286-8010
(domestic) or 617-801-6888 (international) and entering passcode 71511299. The
call also will be archived for 90 days at http://www.streetevents.com,
http://www.fulldisclosure.com and http://www.cytomedix.com.
About Sorin Group
Sorin Group (http://www.sorin.com) is a global, medical device company and a
leader in the treatment of cardiovascular diseases. The Company develops,
manufactures and markets medical technologies for cardiac surgery and for the
treatment of cardiac rhythm disorders. With 3,500 employees worldwide, the Group
focuses on three major therapeutic areas that include: cardiopulmonary bypass
(extracorporeal circulation and autotransfusion systems), cardiac rhythm
management, and heart valve repair and replacement. Every year, over 1 million
patients are treated with Sorin Group devices in more than 80 countries.
About Cytomedix
Cytomedix is a biotechnology company that develops, sells, and licenses
regenerative biological therapies, to primarily address the areas of wound care,
inflammation, and angiogenesis. The Company currently markets the AutoloGel(TM)
System, a device for the production of platelet rich plasma ("PRP") gel derived
from the patient's own blood. The AutoloGel(TM) System is cleared by the Food and
Drug Administration ("FDA") for use on a variety of exuding wounds. The Company
is currently pursuing a multi-faceted strategy to penetrate the chronic wound
market with its AutoloGel(TM) System. We are also pursuing opportunities for the
application of AutoloGel(TM) and PRP technology into other markets such as hair
transplantation and orthopedics, as well as actively seeking complementary
products for the wound care market. The Company also seeks to monetize other
product candidates in its pipeline through strategic partnerships, out-licensing,
or sale. Most notably is its anti-inflammatory peptide (designated "CT-112") that
has shown promise in pre-clinical testing. Additional information regarding
Cytomedix is available at http://www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are
forward-looking statements that are intended to fall within the safe harbor rule
for such statements under the Private Securities Litigation Reform Act of 1995.
The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict or control,
including among others, viability and effectiveness of the Company's sales
approach and overall marketing strategies, the outcome of development or
regulatory review of CT-112, commercial success or acceptance by the medical
community, competitive responses, the Company's ability to raise additional
capital and to continue as a going concern, its ability to successfully
commercialize its product in Japan under the terms of the license agreement, and
Cytomedix's ability to execute on its strategy to market the AutoloGel(TM) System
as contemplated, the Company's ability to successfully integrate this
acquisition, to assume and satisfy certain liabilities related to the acquired
business, or its ability to service the deferred payments on the acquisition.
These forward-looking statements are subject to known and unknown risks and
uncertainties that could cause actual events to differ from the forward-looking
statements. More information about some of these risks and uncertainties may be
found in the reports filed with the Securities and Exchange Commission by
Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing
business and regulatory environment, thus new or unforeseen risks may arise.
Accordingly, investors should not place any reliance on forward-looking
statements as a prediction of actual results. Except as is expressly required by
the federal securities laws, Cytomedix undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new information,
changed circumstances or future events or for any other reason.
This news release was distributed by GlobeNewswire, http://www.globenewswire.com
SOURCE: Cytomedix, Inc.
CONTACT: Cytomedix, Inc.
David Jorden, Executive Board Member
Martin Rosendale, CEO
(240) 499-2680
Lippert/Heilshorn & Associates
Anne Marie Fields
(212) 838-3777
afields@lhai.com
Bruce Voss
(310) 691-7100
bvoss@lhai.com
Advisory committee meeting is in early May... Positive outcome could provide a nice pop in pps, IMO.
GLTA.
Link to recent webcast @ Cowen & Company Healthcare Conference:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=QCOR&item_id=2755230
Lots of potential here w/ QCOR, IMO.
GLTA>
Looks good -- added it to the 2Q list in the iBox. Thanks!
BioShockers Alert
Picked up some QCOR @ $8.66...
Also picked up some AVNR @ $3.04...
GLTA.
Update: Rexahn Pharmaceuticals to Present at Nasdaq Marketsite
Apr 12, 2010 (GlobeNewswire via COMTEX) --
Media and Investors Invited to the MarketSite, Times Square
Tuesday, April 13, 2010, 12:15pm EDT, Others Invited to Video Webcast
ROCKVILLE, Md., April 12, 2010 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc.
(RNN), a clinical stage pharmaceutical company commercializing potential best in
class oncology and CNS therapeutics, today announced that Dr. Chang Ahn, Rexahn's
Chief Executive Officer, will present at the NASDAQ MarketSite in Times Square,
New York City.
Dr. Ahn will discuss Rexhan's important corporate developments in conjunction
with a simultaneously issued press release.
When: April 13, 2010, 12:15 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY
Investors and media are welcome to attend: RSVP required for building security:
212 699-0999 or christina.flood@muncmedia.com
Video Webcast: Click here to schedule the LIVE WEBCAST LINK into your Outlook
calendar. Select "open" then "save and close" when prompted. Click here to watch
the event 4/13, 12:15pm
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to
commercializing first in class and market leading therapeutics for cancer, CNS
disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has
three drug candidates in Phase II clinical trials, Archexin(R), Serdaxin(R), and
Zoraxel(TM) - all potential best in class therapeutics - and a robust pipeline of
preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also
operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery
platforms. For more information, please visit http://www.rexahn.com.
Safe Harbor
This press release contains forward-looking statements. Rexahn's actual results
may differ materially from anticipated results, and expectations expressed in
these forward-looking statements, as a result of certain risks and uncertainties,
including Rexahn's lack of profitability, and the need for additional capital to
operate its business to develop its product candidates; the risk that Rexahn's
development efforts relating to its product candidates may not be successful; the
possibility of being unable to obtain regulatory approval of Rexahn's product
candidates; the risk that the results of clinical trials may not be completed on
time or support Rexahn's claims; demand for and market acceptance of Rexahn's
drug candidates; Rexahn's reliance on third party researchers and manufacturers
to develop its product candidates; Rexahn's ability to develop and obtain
protection of its intellectual property; and other risk factors set forth from
time to time in our filings with the Securities and Exchange Commission. Rexahn
assumes no obligation to update these forward-looking statements.
http://bhsmith.typepad.com/EVENTS/REXAHN%20PHARMACEUTICALS%20Media%20and%20Investor%20Conference.ics
This news release was distributed by GlobeNewswire, http://www.globenewswire.com
SOURCE: Rexahn Pharmaceuticals, Inc.
CONTACT:Stern Investor Relations, Inc.
Investor Relations
Stephanie Ascher
212-362-1200
stephanie@sternir.com
Base Pair Communications
Constantine Theodoropulos
617-401-3116
constantine@basepaircomm.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
Inhibitex Reports Results of Interim Analysis of Phase II Clinical Trial of
FV-100
Trial Continues as Planned after Scheduled DSMB Safety Review and Interim
Analysis
ATLANTA, Apr 12, 2010 (BUSINESS WIRE) -- Inhibitex, Inc. (INHX) today announced
that the independent Data Safety Monitoring Board (DSMB) responsible for
reviewing safety data from the Company's ongoing Phase II clinical trial of
FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up
data on the first half of the patients that the Company plans to enroll in the
trial. In addition, an independent statistician conducted a prospectively
described interim analysis on the primary endpoint, which is the reduction in a
composite of the severity and duration of shingles-associated pain over the first
thirty (30) days of follow-up. Based upon the results of these reviews, the trial
will continue, as originally designed, without modification. The Company, which
remains blinded to the efficacy data, anticipates that top-line data from the
completed trial will be available in the fourth quarter of 2010.
The Phase II trial is a well-controlled, double-blind study comparing two arms of
FV-100, which the Company is developing for the treatment of shingles, to an
active control (valacyclovir). The Company plans to enroll and randomize
approximately 350 shingles patients, aged 50 years and older, equally to one of
three treatment arms: 200 mg FV-100 administered once daily; 400 mg FV-100
administered once daily; and 1,000 mg valacyclovir administered three times per
day. In addition to further evaluating its safety, the objectives of the trial
are to evaluate the potential therapeutic benefit of FV-100 in reducing the
severity and duration of shingles-associated pain, the incidence of post herpetic
neuralgia (PHN), and the time to lesion healing.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical
company focused on developing products to prevent and treat serious infectious
diseases. The Company's pipeline includes FV-100 and INX-189, a nucleotide
polymerase inhibitor in development for the treatment of chronic hepatitis C
infections. The Company has additional HCV nucleotide polymerase inhibitors in
preclinical development, and has also licensed the use of its proprietary
MSCRAMM(R) protein platform to Pfizer for the development of staphylococcal
vaccines.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that involve substantial risks
and uncertainties. All statements, other than historical facts included in this
press release, including statements regarding the anticipated time to complete
and have top-line data available from its ongoing Phase II trial, and the
anticipated number of patients the Company plans to enroll in this trial, are
forward looking statements. These intentions, expectations, or results may not be
achieved in the future and various important factors and risks could cause actual
results or events to differ materially from the forward-looking statements that
the Company makes, including the risk of: either the Company, the FDA, an
investigational review board, or the DSMB suspending or terminating the clinical
development of FV-100 for safety concerns, manufacturing issues or lack of
efficacy; FV-100 not demonstrating sufficient efficacy in reducing the incidence
and severity of shingles-related symptoms, including acute pain and PHN, to be
clinically relevant or commercially viable; the clinical sites participating in
the FV-100 Phase II trial not being able to recruit a sufficient number of
shingles patients to complete the trial on a timely basis; and obtaining,
maintaining and protecting the intellectual property incorporated into and
supporting the commercial viability of the Company's product candidates. Further
information regarding these factors and risks can be found in the Company's
Annual Report on Form 10-K for the year ended December 31, 2009, as filed with
the Securities and Exchange Commission, or SEC, on March 26, 2010. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements, which apply only as of the date of this press release.
There may be events in the future that the Company is unable to predict
accurately, or over which it has no control. The Company's business, financial
condition, results of operations and prospects may change. The Company may not
update these forward-looking statements, even though its situation may change in
the future, unless it has obligations under the Federal securities laws to update
and disclose material developments related to previously disclosed information.
The Company qualifies all of the information contained in this press release, and
particularly its forward-looking statements, by these cautionary statements.
Inhibitex(R) and MSCRAMM(R) are registered trademarks of Inhibitex, Inc.
SOURCE: Inhibitex, Inc.
Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
rplumb@inhibitex.com
or
The Trout Group
Lee Stern, 646-378-2922
lstern@troutgroup.com
Copyright Business Wire 2010
Encouraging Data From Malaria Study Presented
GAITHERSBURG, Md., April 12, 2010 /PRNewswire via COMTEX/ -- GenVec, Inc. (GNVC)
announced that encouraging clinical and preclinical malaria vaccine data were
presented at the Keystone Symposium -- Malaria: New Approaches to Understanding
Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain,
Colorado.
Safety, tolerability, immunogenicity, and efficacy data from the Phase 1/2a
malaria trial using GenVec technology were presented. Data indicate malaria
vaccines given to malaria-naive adults were found to be safe and well-tolerated
with minimal local or systemic reactions and no serious vaccine-related adverse
reactions. Sterile protection, a complete absence of parasites in the blood, was
seen in 4 out of 15 volunteers that had been inoculated with the vaccine and
subsequently challenged with the malaria parasite.
This clinical trial is being conducted under sponsorship from the United States
Army Medical Materiel Development Activity (USAMMDA) and with financial support
from the U.S. Agency for International Development, the Congressionally Directed
Peer Review Medical Program, and the Military Infectious Diseases Research
Program.
"The results of this study are encouraging and we are looking forward to gaining
more insight regarding the potential for this vaccine," stated Dr. Douglas
Brough, GenVec's Vice President of Research.
About Malaria
Malaria is one of the world's leading lethal infectious diseases. Malaria is a
life-threatening disease transmitted to humans through the bite of an infected
mosquito. Malaria parasites initially invade liver cells and, after multiplying,
release tens of thousands of new parasites, which invade red blood cells,
multiply again, and then destroy these cells. High fever, headache, and vomiting
appear approximately nine to fourteen days after the infectious bite. If
untreated, the infection can progress rapidly and become life threatening --
destroying red blood cells, causing severe anemia, and blocking capillaries that
carry blood to the brain, resulting in coma and/or death. Malaria causes
approximately 243 million acute illnesses and 863,000 deaths annually, mostly
among children under the age of five. Malaria is a major health risk for
travelers and the military.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs
and vaccines. GenVec uses its proprietary adenovector technology to develop
TNFerade for the treatment of certain cancers and vaccines for infectious
diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory
syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel
treatments for hearing loss and balance disorders through a worldwide
collaboration with Novartis. Additional information about GenVec is available at
http://www.genvec.com and in the Company's various filings with the Securities
and Exchange Commission.
Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters, including
expectations regarding future revenues and operating expenses, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act. GenVec cautions that these forward-looking statements are
subject to numerous assumptions, risks and uncertainties, which change over time.
Factors that may cause actual results to differ materially from the results
discussed in the forward-looking statements or historical experience include
risks and uncertainties, including the failure by GenVec to secure and maintain
relationships with collaborators; risks relating to the early stage of GenVec's
product candidates under development; uncertainties relating to clinical trials;
risks relating to the commercialization, if any, of GenVec's proposed product
candidates; dependence on the efforts of third parties; dependence on
intellectual property; and risks that we may lack the financial resources and
access to capital to fund our operations. Further information on the factors and
risks that could affect GenVec's business, financial conditions and results of
operations, are contained in GenVec's filings with the U.S. Securities and
Exchange Commission (SEC), which are available at http://www.sec.gov. These
forward-looking statements speak only as of the date of this press release, and
GenVec assumes no duty to update forward-looking statements.
Investor Contact:Media Contact:
Tiberend Strategic Advisors,
GenVec, Inc.Inc.
Danielle M.
DiPirroAndrew Mielach
(301) 944-1877(212) 827-0020
ddipirro@genvec.comamielach@tiberendstrategicadvisors.com
SOURCE GenVec, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
Somaxon Pharmaceuticals Appoints Chief Financial Officer and Announces Senior Leadership Promotions
SAN DIEGO, Apr 12, 2010 (BUSINESS WIRE) -- Somaxon Pharmaceuticals, Inc. (SOMX),
a specialty pharmaceutical company focused on the in-licensing, development and
commercialization of proprietary branded pharmaceutical products and late-stage
product candidates for the treatment of diseases and disorders in the central
nervous system therapeutic area, today announced the appointment of Tran B.
Nguyen as Vice President and Chief Financial Officer. The company also announced
other executive management team updates.
"Tran's finance experience in the life science industry makes him an excellent
addition to the Somaxon team," said Richard W. Pascoe, Somaxon's President and
Chief Executive Officer. "Tran's hiring rounds out our senior management team,
and enhances our ability to execute on our corporate strategy by focusing on our
key objectives of establishing a U.S. commercial partnership, building a U.S.
commercial presence and preparing to launch Silenor in the second half of 2010."
Mr. Nguyen brings to Somaxon over 10 years of finance experience primarily
focused in the life science industry. Mr. Nguyen was most recently Chief
Financial Officer of Metabasis Therapeutics, Inc., a publicly traded
biopharmaceutical company that was acquired by Ligand Pharmaceuticals
Incorporated in January 2010. Prior to Metabasis, Mr. Nguyen was a Vice President
in the healthcare investment banking groups at Citi Global Markets, Inc. and
Lehman Brothers, Inc. where he successfully executed numerous capital raising and
strategic transactions for life science clients.
Central to the execution of Somaxon's strategy is an executive leadership team
capable of driving the company toward its long-term financial and strategic
goals. To that end, Somaxon also announced the following management updates, each
effective April 1, 2010:
-- Jeffrey Raser was promoted to the newly created role of Senior Vice President
and Chief Commercial Officer. In this role, Mr. Raser will be responsible for all
of Somaxon's sales, marketing, managed care and other commercial operations.
-- Brian Dorsey was promoted to Senior Vice President, Technical Operations. In
this role, Mr. Dorsey will manage all of Somaxon's activities relating to
research and development, regulatory affairs, medical affairs, manufacturing and
quality.
-- Matthew Onaitis was promoted to Senior Vice President and General Counsel. In
this role, Mr. Onaitis will manage all of Somaxon's legal, compliance,
intellectual property and business development activities.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty
pharmaceutical company focused on the in-licensing, development and
commercialization of proprietary branded pharmaceutical products and late-stage
product candidates for the treatment of diseases and disorders in the central
nervous system therapeutic area. Somaxon's product Silenor(R) (doxepin) has been
approved by the FDA for the treatment of insomnia characterized by difficulty
with sleep maintenance.
For more information, please visit the company's web site at
http://www.somaxon.com.
Somaxon cautions readers that statements included in this press release that are
not a description of historical facts are forward-looking statements. For
example, statements regarding the potential commercialization of Silenor and the
potential to establish a commercial partnership or other strategic transaction
are forward-looking statements. The inclusion of forward-looking statements
should not be regarded as a representation by Somaxon that any of its plans will
be achieved. Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in Somaxon's business,
including, without limitation, Somaxon's ability to successfully commercialize
Silenor; the potential to enter into and the terms of any commercial partnership
or other strategic transaction relating to Silenor; the scope, validity and
duration of patent protection and other intellectual property rights for Silenor;
whether the approved label for Silenor is sufficiently consistent with such
patent protection to provide exclusivity for Silenor; Somaxon's ability to
operate its business without infringing the intellectual property rights of
others; the market potential for insomnia treatments, and Somaxon's ability to
compete within that market; inadequate therapeutic efficacy or unexpected adverse
side effects relating to Silenor that could delay or prevent commercialization,
or that could result in recalls or product liability claims; the ability of
Somaxon to ensure adequate and continued supply of Silenor to successfully launch
commercial sales or meet anticipated market demand; other difficulties or delays
in development, testing, manufacturing and marketing of Silenor; the timing and
results of non-clinical studies and post-approval regulatory requirements for
Silenor, and the FDA's agreement with Somaxon's interpretation of such results;
Somaxon's ability to raise sufficient capital and meet its obligations to parties
under financing agreements, and the impact of any such financing activity on the
level of Somaxon's stock price; the impact of any inability to raise sufficient
capital to fund ongoing or planned operations; and other risks detailed in
Somaxon's prior press releases as well as in its periodic filings with the
Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement, and
Somaxon undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. This caution is made under
the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.
SOURCE: Somaxon Pharmaceuticals, Inc.
PondelWilkinson, Inc.
Rob Whetstone, 310-279-5963
Copyright Business Wire 2010
Q2 BioStocks to watch list is in the iBOX... DD on those to come soon, then I'll send out an email to the email subscribers...
GLTA.
Going to work on the iBOX today... If any of you have any good ideas as what else we should put in there, post here or PM me...
We called RNN back in December @ 0.67
Friday, they closed @ $2.65 (according to Google Finance)
Great call on NWBO -- it's up 0.30 (27.52%) today.
DCTH up 0.42 (4.44%)
RNN up 0.20 (8.55%)
Good morning all!
NexMed Inc Files $30M Mixed-Securities Shelf>NEXM
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2400)
04-08-10 1618ET
Copyright (c) 2010 Dow Jones & Company, Inc.
16:18 040810
Senesco Technologies Receives Notice of Non Compliance From NYSE Amex
NEW BRUNSWICK, N.J., April 8, 2010 /PRNewswire via COMTEX/ -- Senesco
Technologies, Inc. (the "Company") (SNT) has received a notice from the NYSE Amex
LLC ("NYSE") providing notification that the Company does not meet one of the
NYSE's continued listing standards as set forth in Part 10 of the NYSE company
guide and the Company has therefore become subject to the procedures and
requirements of Section 1009 of the NYSE company guide. Specifically, the Company
is not in compliance with Section 704 of the NYSE company guide in that it failed
to hold an annual meeting of its stockholders during the year ended December 31,
2010.
To maintain an NYSE listing, Senesco must submit a plan by April 15, 2010
advising the NYSE of action it has taken, or will take, that would bring Senesco
into compliance with the continued listing standards by July 1, 2010. The Company
is taking steps to prepare and submit such a plan to the NYSE on or before April
15, 2010.
As previously disclosed, the Company recently executed a financing and must seek
stockholder approval of certain aspects of the financing. Therefore, the Company
anticipates that it will simultaneously hold its annual meeting at the same time
it holds a meeting to seek stockholder approval of certain aspects of the
financing. The Company expects to file a proxy statement, which will include the
information on its annual meeting, in the near future.
The Listings Qualifications Department of the NYSE will evaluate Senesco's plan
and determine whether it reasonably demonstrates the Company's ability to regain
compliance with the continued listing standards by July 1, 2010. If the NYSE
accepts Senesco's plan, the Company may be able to continue its listing during
the plan period, provided that Senesco demonstrates progress consistent with its
plan and complies with other applicable NYSE listing qualifications. If the
Company fails to submit a satisfactory plan or fails to demonstrate progress
consistent with the plan accepted by the NYSE, the NYSE may initiate delisting
procedures. During the plan period, Senesco will be subject to periodic review to
determine whether it is achieving progress consistent with the plan.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New
Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay
cell death in mammals (apoptosis) to determine if the technology is applicable in
human medicine. Accelerating apoptosis may have applications to development of
cancer treatments. Delaying apoptosis may have applications to certain
inflammatory and ischemic diseases. Senesco takes its name from the scientific
term for the aging of plant cells: senescence. Delaying cell breakdown in plants
extends freshness after harvesting, while increasing crop yields, plant size and
resistance to environmental stress. The Company believes that its technology can
be used to develop superior strains of crops without any modification other than
delaying natural plant senescence. Senesco has partnered with leading-edge
companies engaged in agricultural biotechnology and earns research and
development fees for applying its gene-regulating platform technology to enhance
its partners' products.
Certain statements included in this press release are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results could differ materially from such statements expressed or implied
herein as a result of a variety of factors, including, but not limited to: the
ability of the Company to consummate additional financings; the development of
the Company's gene technology; the approval of the Company's patent applications;
the successful implementation of the Company's research and development programs
and joint ventures; the success of the Company's license agreements; the
acceptance by the market of the Company's products; success of the Company's
preliminary studies and preclinical research; competition and the timing of
projects and trends in future operating performance, the Company's ability to
comply with the continued listing standards of the AMEX, as well as other factors
expressed from time to time in the Company's periodic filings with the Securities
and Exchange Commission (the "SEC"). As a result, this press release should be
read in conjunction with the Company's periodic filings with the SEC. The
forward-looking statements contained herein are made only as of the date of this
press release, and the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
Company Contact:Investor Relations Contact:
-------------------------------------------
Senesco Technologies, Inc.FD
Jack Van HulstBrian Ritchie
Chief Executive Officer(brian.ritchie@fd.com)
(jvanhulst@senesco.com)(212) 850-5683
(732) 296-8400
SOURCE Senesco Technologies, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
Picked up some RNN here @ $2.31...
14 Biotech Stocks Facing FDA Approval:
http://www.thestreet.com/story/10719163/1/14-biotech-stocks-facing-fda-approval.html
We called DCTH (Delcath Systems, Inc.) @ $5.32 in February. Today, it's trading @ $9.33
Link back for original DCTH post...
Potential BioShocker - QCOR (Questcor Pharmaceuticals, Inc.)
Upcoming advisory panel meeting and PDUFA date.
Drug: Acthar for infantile spasms
PDUFA date: June 11
An FDA advisory panel will review the safety and efficacy of Acthar on May 6. The FDA's review of Acthar is expected to post to the agency's web site on May 4 or May 5.
IntelGenx to Present at BioFinance 2010
SAINT LAURENT, QUEBEC, Apr 07, 2010 (MARKETWIRE via COMTEX) -- IntelGenx Corp.
(CA:IGX)(IGXT) ("IntelGenx") today announced that that Dr. Horst Zerbe, President
and Chief Executive Officer, will present an overview of the Company at the
BioFinance 2010 Conference, which is taking place this week in Toronto. Dr. Zerbe
will be speaking this afternoon at 4:30pm EDT.
Dr. Zerbe will discuss advances made in our pipeline and technologies. In the
past year we filed an NDA for our high dose Bupropion XL product, and we received
excellent data on both our Relivar product (a novel buccal formulation of a
dronabinol) and on our thin film migraine product. These milestones validate our
best in class VersaTab, VersaFilm and AdVersa technologies.
About BioFinance 2010:
BioFinance 2010 is the leading investor conference in Canada for the life
sciences industry. This event brings together key industry players interested in
investment opportunities and issues affecting companies in the life sciences
sector.
About IntelGenx Corp.:
IntelGenx Corp. is a drug delivery company focused on the development of oral
controlled-release products as well as novel rapidly disintegrating delivery
systems. IntelGenx uses its unique multiple layer delivery system to provide
zero-order release of active drugs in the gastrointestinal tract. IntelGenx has
also developed novel delivery technologies for the rapid delivery of
pharmaceutically active substances in the oral cavity based on its experience
with rapidly disintegrating films. IntelGenx's research and development pipeline
includes products for the treatment of pain, hypertension, osteoarthritis and
depressive disorders. More information is available about the company at
http://www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx's operating
results and business prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934, as amended,
and Section 27A of the Securities Act of 1933, as amended. These statements
include, but are not limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of future events
or circumstances and are generally identified by the words "may," "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," "could,"
"would," and similar expressions. All forward looking statements are expressly
qualified in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and uncertainties,
IntelGenx's actual results could differ materially from those expressed or
implied by these forward looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, those discussed
under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K for
the fiscal year ended December 31, 2008, filed with the United States Securities
and Exchange Commission and available at http://www.sec.gov, and also filed with
Canadian securities regulatory authorities and http://www.sedar.com. IntelGenx
assumes no obligation to update any such forward-looking statements.
Each of the TSX Venture Exchange and OTC Bulletin Board has neither approved nor
disapproved the contents of this press release.
Contacts:
IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
+1 514-331-7440 (ext. 201)
+1 514-331-0436 (FAX)
horst@intelgenx.com
http://www.intelgenx.com
SOURCE: IntelGenx Corp.
mailto:horst@intelgenx.com
http://www.intelgenx.com
Copyright 2010 Marketwire, Inc., All rights reserved.
Nile Therapeutics Announces Proposed Public Offering
SAN MATEO, Calif., April 6 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq:NLTX - News), a company focused on the development of novel therapeutics for heart failure patients, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering. Maxim Group LLC is acting as the sole book-running manager for this offering, with Ladenburg Thalmann & Co. Ltd. as co-manager.
The Company plans to use the net proceeds from this offering to fund the previously announced expansion of its ongoing Phase II clinical trial of CD-NP in acute heart failure patients, and for general corporate purposes and working capital. The offering is being made pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. When available, copies of the prospectus supplement relating to this offering may be obtained from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, or by telephone at 212-895-3685.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, units, shares of common stock or warrants. Furthermore, Nile will not sell any of the units and has been advised by Maxim Group that the underwriters and their affiliates will not sell any of the units in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the securities under the securities laws of any such state or jurisdiction.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.
Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the proposed offering, the timing, progress and anticipated results of Nile's ongoing clinical trial, and the anticipated benefits of CD-NP, are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's ability to complete the proposed offering, Nile's need to raise additional capital to fund its product development programs to completion, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
NITE back to .11. LOL. The MMs never learn...
NLTX hasn't been this low since June '09... May be a good time to enter in, IMO.
GLTA.
Theratechnologies to Present at BioFinance 2010 Conference
MONTREAL, CANADA -- (MARKETWIRE) -- 04/05/10 --
Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and
Chief Executive Officer, will present an overview of the Company at the
BioFinance 2010 Conference, being held this week in Toronto. Mr. Rosconi will
be speaking at 11:00 a.m., on Wednesday, April 7, in the Trinity II Room of the
Toronto Marriott Eaton Centre.
BioFinance is the Canadian life science industry's leading investor
conference that brings together key industry players to consider investment
opportunities and issues affecting companies in biotechnology.
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that
discovers and develops innovative therapeutic products, with an emphasis on
peptides, for commercialization. The Company targets unmet medical needs in
financially attractive specialty markets where it can retain all or part of the
commercial rights to its products. Its most advanced compound, tesamorelin, is
an analogue of the human growth hormone releasing factor. In 2009,
Theratechnologies submitted a New Drug Application to the U.S. Food and Drug
Administration, seeking approval of tesamorelin for the treatment of excess
abdominal fat in HIV-infected patients with lipodystrophy. The Company's growth
strategy is centered on the commercialization of tesamorelin in the United
States and in other markets for HIV-associated lipodystrophy, as well as the
development of clinical programs for tesamorelin in other medical conditions.
Contacts: Theratechnologies Inc. Andrea Gilpin Vice President, IR &
Communications 514-336-7800, ext. 205 communications@theratech.co
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=zKXWTTW28PrVwqlfsS6Erg%3D%3D. You can use
this link on the day this article is published and the following day.
(END) Dow Jones Newswires
04-05-10 1037ET
Will be re-doing the iBOX this week... Time to get this board up and running!
Nabi Biopharmaceuticals Prevails in Opposition to Drug Abuse Therapy Patent
ROCKVILLE, Md., April 5, 2010
GLOBE NEWSWIRE
Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that the European Patent Office (EPO) upheld the Company's opposition to European Patent No. 1,329,226 (Hapten Carrier Conjugates for Use in Drug Abuse Therapy) requesting revocation of this patent. The EPO revoked this patent in its entirety.
The patent was filed by Xenova Research Limited, which was subsequently acquired by Celtic Pharma in 2005. On February 15, 2008, Nabi, along with four other parties, filed an opposition against this patent, requesting revocation of the Xenova patent in its entirety. As a result of this EPO decision, Celtic Pharma has lost its exclusive patent rights to nicotine conjugate vaccine technology in Europe. Xenova Research Limited, still named as the proprietor of the patent, has the opportunity to file a Notice of Appeal within a period of two months from the March 29, 2010 date of the EPO written decision.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX® (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com
Forward-Looking Statements
Statements in this release that are not strictly historical are forward-looking statements and include statements about products in development, results and analyses of clinical trials and studies, research and development expenses, cash expenditures, licensure applications and approvals, and alliances and partnerships, among other matters. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to conduct and obtain successful results from our two Phase III clinical trials for NicVAX; GSK's failure to exercise its option for and successfully commercialize NicVAX; GSK's failure to successfully develop and commercialize any future generation candidate nicotine vaccine; our ability to commercialize NicVAX if GSK does not exercise its option for NicVAX; our ability to raise sufficient new capital resources to fully develop and commercialize NicVAX if GSK does not exercise the NicVAX option; our ability to attract, retain and motivate key employees; our ability to collect any further milestones and royalty payments under the PhosLo and PentaStaph agreements; the ability to obtain regulatory approval for NicVAX and any future generation candidate nicotine vaccine in the U.S. or other markets; our ability to successfully contract with contract manufacturing organizations for the manufacture and supply of NicVAX; our ability to comply with reporting and payment obligations under government rebate and pricing programs; and loss of full use of our net operating loss carry forwards. These factors are more fully discussed, as are other factors, in our Annual Report on Form 10-K for the fiscal year ended December 26, 2009 filed with the Securities and Exchange Commission.
CONTACT: Nabi Biopharmaceuticals
Investor Relations
301-770-3099
www.nabi.com
Fibrocell Science, Inc. Announces Addition of Marc B. Mazur to Board of Directors
EXTON, Pa., April 6 /PRNewswire-FirstCall/ --
Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications, announced today that Marc B. Mazur has been appointed to its board of directors, effective April 1, 2010.
Mr. Mazur is the Chairman of Elsworthy Capital Management Ltd., a London-based European equity hedge fund with assets in excess of $100 million. Most recently, he was the CEO of Brevan Howard U.S. Asset Management, the U.S. arm of London-based Brevan Howard, Europe's largest hedge fund. Prior to joining Brevan Howard, Mr. Mazur had been a senior advisor to both Tsinghua Venture Capital Company (a subsidiary of Tsinghua Holdings, the investment arm of Tsinghua University in Beijing) and Think Equity Partners LLC, a San Francisco investment bank focusing on emerging growth companies in biotechnology, software and greentech.
"As a consultant and private investor with more than 25 years of experience in risk management, business development and senior level sales and marketing within the financial services and health care fields, Marc brings great perspective to the Fibrocell Science board of directors," said Chairman and CEO David Pernock. "We look forward to working with him as we seek to secure U.S. Food & Drug Administration (FDA) approval for our lead therapy's (azficel-T) use in the treatment of moderate to severe nasolabial fold wrinkles."
Mr. Mazur began his career in 1984 at Salomon Brothers in London as a Eurobond trader. In 1987 he joined Goldman Sachs as a Vice President in the fixed income division. He was employed by Goldman from 1987 through 1996 on a full-time basis and subsequently as a consultant from 1997 through 1999. In 1997 Mr. Mazur became an independent consultant, managing business development opportunities in the financial services sector for Goldman Sachs and leveraging his expertise in risk and disease management for public and private companies in the healthcare field. Continuing in healthcare, in 1998 Mr. Mazur was named Vice President for strategic business development at CareInsite (subsequently acquired by WebMD). In 2001 Mr. Mazur founded Ambassador Capital Group, a privately held investment and advisory entity providing capital, business development and strategic planning advice to companies in the healthcare, financial services and real estate fields. He has also been an active angel and venture investor in numerous biotechnology and healthcare device start-ups.
Mr. Mazur is an active member of numerous charitable and educational organizations and has served as a board member and advisory board member of numerous public and private companies. He received his B.A. in political science from Columbia University in 1981 and a J.D. from Villanova University in 1984.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing regenerative fibroblast cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
Forward-Looking Statements
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, without limitation, the ability of the Company to secure FDA approval for its lead therapy's (azficel-T) use in the treatment of moderate to severe nasolabial fold wrinkles. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.
SOURCE Fibrocell Science, Inc.